This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

NovaBay Pharmaceuticals To Present At 2011 Biotech Showcase Conference

CEO Dr. Ron Najafi to Provide Corporate Presentation and Participate on Panel Addressing New Treatments for Infectious Diseases

EMERYVILLE, Calif., Jan. 7, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective Aganocide® compounds for the topical treatment and prevention of antibiotic-resistant infections, will present at the 2011 Biotech Showcase Conference being held at the Parc 55 Wyndham San Francisco - Union Square. Dr. Ron Najafi, NovaBay's Chief Executive Officer, will address attendees on Tuesday, January 11, 2011 at 11:00 AM Pacific Time.

Dr. Najafi will also participate in a panel discussion on the infectious disease landscape titled "Infectious Disease:  A War on Many Fronts - Can It Be Won?" The panel discussion will take place on Wednesday, January 12, 2011 from 8:00 AM - 9:00 AM at the Parc 55 Wyndham Hotel. 

Panel Discussion Overview:

On one front, viral infections have proven to be one of man's toughest foes. While H1N1, H5N1 and SARS grab world headlines, the biotech industry is in an ongoing battle with HIV, hepatitis and the more exotic Ebola and dengue fever. On another front, bacterial infections are becoming more and more difficult to treat because of antibiotic resistance. While MRSA is best known, bacterial resistance is developing against every antibiotic in use today and solutions are still on the horizon. A panel of CEO's developing an arsenal of next generation antiviral and antimicrobial weapons will discuss the infectious disease landscape and their technologies and targets.

More information about the 2011 Biotech Showcase Conference is available at http://www.ebdgroup.com/bts/index.php .

To arrange a meeting with NovaBay management, please contact Adam Holdsworth at 212-825-3210, or e-mail adam@investorrelationsgroup.com.

About NovaBay's Aganocide Compounds

NovaBay's Aganocide compounds are novel, synthetic N-chlorinated antimicrobial molecules specifically designed and developed to mimic the body's natural defense against infection. These compounds maintain biological activities while demonstrating improved stability over the naturally occurring N-chlorinated antimicrobial molecules. In preclinical testing, Aganocide compounds have been shown to be highly effective against bacteria, including some multi-drug resistant strains (such as MRSA), viruses and fungi. NovaBay's Aganocide compounds have the potential to deliver the same or better efficacy than antibiotics, and to address the growing problem of antibiotic resistance by employing a novel mechanism of action.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs